These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15694513)

  • 1. Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation.
    Plikaytis BD; Carlone GM
    Vaccine; 2005 Feb; 23(13):1606-14. PubMed ID: 15694513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis.
    Plikaytis BD; Carlone GM
    Vaccine; 2005 Feb; 23(13):1596-605. PubMed ID: 15694512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical considerations for noninferiority/equivalence trials in vaccine development.
    Wang WW; Mehrotra DV; Chan IS; Heyse JF
    J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of studies to evaluate immune response to combination vaccines.
    Horne AD; Lachenbruch PA; Getson PR; Hsu HS
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S306-11. PubMed ID: 11709764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine efficacy determination.
    Broome CV
    NIPH Ann; 1991 Dec; 14(2):219-21; discussion 222-4. PubMed ID: 1812435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new endpoint definition improved clinical relevance and statistical power in a vaccine trial.
    Pédrono G; Thiébaut R; Alioum A; Lesprit P; Fritzell B; Lévy Y; Chêne G
    J Clin Epidemiol; 2009 Oct; 62(10):1054-61. PubMed ID: 19282146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation.
    Li X; Wang WW; Liu GF; Chan IS
    J Biopharm Stat; 2011 Mar; 21(2):294-310. PubMed ID: 21391003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I error and power in noninferiority/equivalence trials with correlated multiple endpoints: an example from vaccine development trials.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2004 Nov; 14(4):893-907. PubMed ID: 15587971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
    Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
    Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?
    Pfleiderer M
    Biologicals; 2009 Nov; 37(6):364-8. PubMed ID: 19773184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
    Kohberger RC
    Stat Med; 2009 Jan; 28(1):177-8, author reply 178-9. PubMed ID: 18937271
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.